From 6 Hot Flashes a Day to 2: Fezolinetant's Japan Phase 3 Trial Succeeds
Hot flashes are the signature symptom of menopause, but the numbers behind them tell the fuller story. Women experiencing ten or more moderate to severe hot flashes per day are not uncommon. Studies tracking women over time find that a third of them deal with vasomotor symptoms for more than seven years. The disrupted sleep, fractured concentration, and constant interruption to daily life compound into something well beyond discomfort.
On February 3, 2026, Astellas Pharma reported that fezolinetant, the non-hormonal oral compound already sold in 36 countries under the name VEOZAH, met its primary endpoint in STARLIGHT 2, a Phase 3 trial conducted exclusively in Japan. Both 30mg and 45mg doses demonstrated statistically significant reductions in hot flash frequency compared to placebo in 410 Japanese women. The data will support regulatory submission in Japan, marking a potential turning point for non-hormonal menopause care across Asia.
What Is Actually Happening in the Brain
To understand why fezolinetant works, it helps to trace the sequence that produces a hot flash.
The hypothalamus is the brain’s thermostat. When estrogen levels decline with menopause, a cluster of neurons inside it, called KNDy neurons (named for the three signaling molecules they release: kisspeptin, neurokinin B, and dynorphin), become hyperactive. These neurons begin firing excessively, and one of their main signals, neurokinin B, binds to a protein called the NK3 receptor. When that receptor is activated in the hypothalamus, the brain reads it as overheating, even when the body temperature is normal. The result is a forced heat-dissipation response: blood vessels near the skin dilate, sweat glands activate, and the familiar wave of heat and flushing follows.
Fezolinetant blocks neurokinin B from binding to the NK3 receptor. It does not touch estrogen levels or any other hormone. The mechanism is precise: cut the false alarm at its source without altering the broader hormonal landscape. This is what separates fezolinetant from earlier non-hormonal options like SSRIs, gabapentin, or clonidine, which were all repurposed from other conditions and work on entirely different, less targeted pathways.
What the STARLIGHT 2 Trial Found
STARLIGHT 2 (NCT06206408) was a 12-week, randomized, double-blind, placebo-controlled, multicenter study. The 410 participants were postmenopausal or perimenopausal Japanese women experiencing vasomotor symptoms. They were randomized to fezolinetant 30mg, fezolinetant 45mg, or placebo, each taken once daily.
The primary endpoint was the change in frequency of moderate to severe hot flashes from baseline to week 8. Both active doses achieved statistically significant superiority over placebo. Serious treatment-emergent adverse events occurred in fewer than 4% of participants. The safety profile was consistent with the established global dataset.
Earlier Japanese data from Phase 2 (STARLIGHT 1, 147 participants) showed that fezolinetant 15mg and 30mg reduced hot flash frequency by 2.50 and 1.76 events per day more than placebo, respectively, with the benefit appearing within the first week and persisting through 12 weeks.
Putting those numbers in context with global trial data: across the SKYLIGHT 1, 2, and 4 Phase 3 trials conducted primarily in North America and Europe, fezolinetant 45mg reduced moderate to severe hot flash frequency by approximately 60 to 65 percent from baseline versus roughly 45 percent with placebo. In those studies, 81 to 95 percent of participants receiving fezolinetant achieved at least a 50 percent reduction in hot flash frequency. Translated to daily life: a woman experiencing ten hot flashes a day could expect to reach two by twelve weeks.
Who This Matters For
For women who can use hormone therapy, HRT remains the most comprehensively effective option. It reduces hot flashes, protects bone density, and has cardiovascular benefits in the right context. The challenge is the sizable group for whom HRT is not an option.
Women with a history of breast cancer, clotting disorders, or hormone-sensitive conditions are frequently excluded from HRT. Those undergoing anti-estrogen treatment for hormone receptor-positive breast cancer, such as tamoxifen or aromatase inhibitors, often see hot flashes worsen as a treatment side effect, creating a compound problem: the cancer therapy itself driving the symptom that most disrupts daily function. Fezolinetant, because it bypasses estrogen entirely, does not carry those hormonal risks.
The one area requiring monitoring is liver function. In global trials, approximately 2 to 3 percent of participants experienced elevated liver enzymes. Regular liver function testing is recommended before starting treatment and through the first nine months. This is the primary clinical consideration in patient selection.
Earlier non-hormonal medications prescribed off-label for hot flashes, such as venlafaxine (an antidepressant) or gabapentin (an anticonvulsant), typically reduce hot flash frequency by around 40 to 60 percent, with variable tolerability and side effect profiles that were not designed with menopausal women in mind. Fezolinetant’s mechanism is purpose-built.
The Significance of an Asia-Specific Dataset
The STARLIGHT 2 results carry a specific implication beyond efficacy confirmation. Virtually all of fezolinetant’s pivotal Phase 3 data before this trial came from predominantly Western populations. Demonstrating that the KNDy pathway behaves the same way in Japanese women, and responds to the same drug at the same doses, provides evidence that this is a universal physiological mechanism, not one shaped by population-specific variables.
Full STARLIGHT 2 results are scheduled for submission and presentation at a scientific congress in late 2026. If Japan’s regulatory approval follows, the pathway to broader Asian market availability becomes clearer, including potential implications for Korea and other markets where menopause care has historically been undertreated.
There is a broader cultural dimension here. Across much of Asia, the expectation that menopause symptoms are simply to be endured has been more entrenched than in Western contexts. Precision tools with solid local data create the conditions for that expectation to change. Fezolinetant is not the only option, and it is not for everyone. But the fact that it works by addressing a specific, well-characterized mechanism, rather than by suppressing symptoms broadly, makes it a more informative addition to the conversation about what managing menopause actually looks like.
Q. Fezolinetant is already FDA-approved. Why does Japan need a separate trial?
The FDA approved fezolinetant in May 2023 based on data from predominantly Western populations. Japan’s regulatory authority, like most national agencies, requires independent clinical evidence in its own population before granting approval. STARLIGHT 2’s 410-patient Japanese dataset will form the basis of Astellas’s regulatory submission in Japan.
Q. How is NK3 receptor blocking different from hormone therapy?
Hormone therapy (HRT) works by replenishing estrogen. Fezolinetant works independently of estrogen levels, directly blocking the NK3 receptor signal that KNDy neurons use to trigger the brain’s faulty heat-release response. This makes it suitable for women who cannot use HRT due to breast cancer history, clotting risk, or personal preference.
Q. When does the effect start, and what should I watch for?
Clinical data shows hot flash frequency starts declining within the first week of use, stabilizing by weeks 8 to 12. Because fezolinetant can affect liver enzymes, a liver function test is recommended before starting and periodically during the first nine months. Anyone with liver disease history should discuss this with their doctor before use.